Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Nasopharyngeal Carcinoma 12Esophageal Neoplasms 9Esophageal Squamous Cell Carcinoma 8Squamous Cell Carcinoma of Head and Neck 7Uterine Cervical Neoplasms 6Pancreatic Neoplasms 4Head and Neck Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Stomach Neoplasms 3Recurrence 2Pancreatic cancer, adult 2Lung Neoplasms 2Diffuse Intrinsic Pontine Glioma 2Uterine Cervical Dysplasia 1Squamous Cell Carcinoma of Anal Canal 1Penile Neoplasms 1Pathologic Complete Response 1Pancreatic Cancer Resectable 1Oropharyngeal Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Meningeal Carcinomatosis 1Locally Advanced Rectal Cancer 1Hypopharyngeal Neoplasms 1HCC 1Glioma 1Glioblastoma 1Esophageal 1Colorectal Neoplasms 1Childhood Brain Stem Neoplasm 1

Interventions

Temozolomide 154Bevacizumab 88Radiotherapy 75Radiation 23Magnetic Resonance Spectroscopy 23Lomustine 18Irinotecan 18pembrolizumab 17Surgical Procedures, Operative 16Carmustine 16Erlotinib Hydrochloride 12Nivolumab 11Specimen Handling 10Aminolevulinic Acid 10sargramostim 9Thalidomide 9Chemotherapy, Adjuvant 9Carboplatin 9Drug Therapy 8Immunoglobulin G 7Filgrastim 7Etoposide 7Disulfides 7Cilengitide 7Sunitinib 6Sorafenib 6O(6)-benzylguanine 6Cyclophosphamide 6antineoplaston AS 2-1 5antineoplaston A10 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Glioblastoma × nimotuzumab × Clear all
NCT03388372 2018-01-03

Nimotuzumab Plus Radiotherapy With Concomitant and Adjuvant Temozolomide for Cerebral Glioblastoma

Biotech Pharmaceutical Co., Ltd.

Phase 2 Completed
39 enrolled
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡